Table 1 Baseline characteristics of the patients included in the study (n = 95)
Variable | N | % |
|---|---|---|
Age | ||
< 70 years old | 79 | (83%) |
≥ 70 years old | 16 | (17%) |
Comorbidities | ||
Hypertension | 13 | (13,7%) |
Dyslipidemia | 9 | (9.5%) |
Diabetes Mellitus | 3 | (3.2%) |
Cardiorespiratory disease | 9 | (9.5%) |
Liver and renal disease | 5 | (5.3%) |
Relevant comorbidity (≥ grade 2) | 12 | (12.6%) |
BMI | ||
BMI < 25 | 43 | (45%) |
BMI 25–30 | 35 | (37%) |
BMI > 30 | 17 | (18%) |
Histology | ||
Infiltrating ductal carcinoma | 84 | (88%) |
Infiltrating lobular carcinoma | 11 | (12%) |
Tumor subtype | ||
ER and/or PgR positive | 75 | (79%) |
Triple Negative | 16 | (17%) |
HER2-positive | 4 | (4%) |
Previous chemotherapies | ||
Taxane | 93 | (98%) |
Capecitabine | 93 | (98%) |
Vinorelbine | 33 | (35%) |
Location of M1 | ||
Bone | 73 | (77%) |
Lymph nodes | 67 | (71%) |
Liver | 62 | (65%) |
Lung | 29 | (31%) |
Pleura | 23 | (24%) |
Central nervous system | 20 | (21%) |
Skin | 19 | (20%) |
Visceral metastases | ||
Yes | 72 | (76%) |
No | 23 | (24%) |
Number of organs involved | ||
≤ 2 organs | 35 | (37%) |
> 2 organs | 60 | (63%) |